Pluslife Wins the "2024 Medical Health Corporate Responsibility Model Award," Leading New Breakthroughs in Tuberculosis Control

Recently, at The 14th Philanthropy Festival and 2024 ESG Summit, Guangzhou Pluslife Biotech Co., Ltd. (hereinafter referred to as "Pluslife") was honored with the "2024 Medical Health Corporate Responsibility Model Award." This prestigious award recognizes Pluslife’s outstanding contributions to global tuberculosis control, public health improvement, and corporate social responsibility, highlighting its global influence as an industry innovation leader.

The "Medical Health Corporate Responsibility Model Award" is one of the key awards at the Philanthropy Festival, designed to recognize companies that have made remarkable achievements in promoting public health and technological innovation. Pluslife will use this honor as an opportunity to continue promoting global health equity and sustainable development, driving tuberculosis control to higher standards in the future.

Technology Innovation Drives Global Health Development

Leveraging its proprietary RHAM technology, Pluslife has developed molecular POCT technologies, instruments, and test cards for major infectious diseases, respiratory infections, reproductive infections, and animal pathogens. To date, Pluslife has applied for over 170 patents and certifications, with more than 50 patents granted and over 120 international certifications. The MiniDock has performed excellently in a molecular diagnostic technology and platform evaluation project by the PATH, demonstrating its broad application potential in resource-limited areas. MiniDock is compact, easy to use, and can detect over 30 pathogens, costing only 1% of traditional equipment, providing strong support to remote healthcare institutions and effectively solving the diagnostic challenges of major infectious diseases like tuberculosis.

Mission and Vision: Empowering Health with Technology, Creating a Tuberculosis-Free Future

Pluslife is dedicated to improving global infectious disease detection, with significant breakthroughs in tuberculosis control. As the recipient of the "Medical Health Corporate Responsibility Model Award," Pluslife is actively promoting the widespread adoption of low-cost, high-performance tuberculosis detection technology, particularly for high-risk populations in resource-limited areas. This effort not only supports the global goal of ending tuberculosis by 2035 but also contributes positively to global public health equity and sustainable development.

Innovative Products: Breaking Technical Barriers, Empowering Primary Healthcare

Pluslife’s rapid molecular diagnostic solution for tuberculosis supports dual sample testing for both sputum and throat swabs. With its four main advantages—innovation, precision, fast, and affordability—this solution provides a higher accessibility and accuracy option for tuberculosis detection.

Innovative Detection Technology: Based on RHAM constant-temperature amplification technology, Pluslife’s tuberculosis rapid molecular diagnostic products offer extremely high sensitivity and specificity, comparable to laboratory PCR tests.
Clinical Performance: A clinical study covering Vietnam and Uganda presented at the 55th World Lung Health Conference (The Union) shows that Pluslife’s throat swab sample for tuberculosis detection has a sensitivity of 89% and a specificity of 100%, demonstrating outstanding performance. The product far exceeds the World Health Organization (WHO) requirements for “near POC non-sputum diagnostic” platforms with sensitivity ≥75% and specificity ≥98%, further confirming its excellence in rapid molecular diagnostics.
Rapid and Convenient: Sample preparation takes only a few minutes, and the detection time ranges from 5 to 25 minutes. Non-professionals can complete the test after simple training, significantly improving testing efficiency and accessibility.
Dual Sample Coverage: Supporting both throat swabs and sputum samples, this solution is especially suitable for children, HIV patients, and other populations unable to collect sputum, providing a broader range of applications in global tuberculosis control.
Low Cost and High Usability: The cost is only 1% of traditional diagnostic products, and it does not require electricity or cold chain storage, drastically reducing active screening costs, making it affordable for resource-limited primary healthcare institutions.

This product has gained widespread recognition in the international market and has become one of the few mature low-cost rapid molecular diagnostic products globally. It has received high praise from authoritative organizations such as the Bill & Melinda Gates Foundation, WHO, and FIND, and has been successfully promoted in countries like Indonesia.

Leading the Future: Achieving Global Health Equity

Through continuous research and promotion of rapid molecular tuberculosis diagnostic technology, Pluslife has not only revolutionized tuberculosis detection methods but also profoundly impacted global infectious disease control strategies. In the future, Pluslife will continue to actively support global public health efforts, contributing to the achievement of global health equity.